Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Gainers
Why Clinuvel, Nitro, Premier Investments, and Pushpay shares are rising
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
8 ASX 200 shares got kicked out of the index on Monday. How are they tracking?
Share Gainers
Why Accent, Bigtincan, Clinuvel, and IVE shares are dropping today
Share Fallers
Why Clinuvel, EML, Infomedia, and Link shares are dropping today
Share Market News
The ASX 200 is getting a shakeup today. Here's the tea
Share Market News
Out in the cold: How are the ASX 200 evictees faring on Monday?
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Investing Strategies
Why these 3 ASX shares could be in for a massive boost this month
Share Market News
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
